Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase 2

Active, not recruiting

Conditions: Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Liver and Intrahepatic Bile Duct Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Unresectable Intrahepatic Cholangiocarcinoma

Interventions: Drug: Dexamethasone
Drug: Floxuridine
Device: Implanted Medical Device
Drug: Irinotecan
Drug: Leucovorin
Drug: Oxaliplatin
Other: Quality-of-Life Assessment

First Posted Date: 2020-02-05

Last Posted Date: 2024-03-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 5

Registration Number: NCT04251715

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Biological: Bevacizumab
Drug: Capecitabine
Drug: Irinotecan
Drug: 5-FU
Drug: CF

First Posted Date: 2020-01-30

Last Posted Date: 2022-03-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 264

Registration Number: NCT04247984

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

9-ING-41 in Pediatric Patients with Refractory Malignancies.

Phase 1

Recruiting

Conditions: Cancer Pediatric
Pediatric Cancer
Pediatric Brain Tumor
Refractory Cancer
Refractory Tumor
Pediatric Meningioma
Neuroblastoma
Neuroblastoma Recurrent
Refractory Neoplasm
Pediatric Lymphoma

Interventions: Drug: 9-ING-41
Drug: Irinotecan
Drug: Cyclophosphamide
Drug: Temozolomide
Drug: Topotecan

First Posted Date: 2020-01-23

Last Posted Date: 2024-11-08

Lead Sponsor: Actuate Therapeutics Inc.

Target Recruit Count: 68

Registration Number: NCT04239092

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 6 locations

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Relapsed Solid Tumor
Refractory Solid Tumor

Interventions: Drug: Abemaciclib
Drug: Irinotecan
Drug: Temozolomide
Drug: Dinutuximab
Drug: GM-CSF

First Posted Date: 2020-01-23

Last Posted Date: 2024-06-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 117

Registration Number: NCT04238819

Locations: 🇦🇺
Perth Children's Hospital, Perth, Western Australia, Australia
🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇧🇪
UZ Gent, Gent, Oost-Vlaanderen, Belgium

and more 22 locations

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Phase 3

Recruiting

Conditions: High-Risk Neuroblastoma
Patient With Insufficient Response Chemoimmunotherapy

Interventions: Radiation: Radiotherapy
Drug: Vincristine
Drug: Busulfan
Drug: Dinutuximab Beta
Drug: Carboplatin
Drug: Melphalan
Drug: Etoposide
Drug: Thiotepa
Drug: Vindesine
Drug: Dacarbazine
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Temozolomide 100 MG
Drug: Irinotecan
Drug: Cyclophosphamid

First Posted Date: 2020-01-09

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT04221035

Locations: 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷
Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹
instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Phase 2

Conditions: HER-2 Protein Overexpression
HER-2 Gene Amplification

Interventions: Drug: Trastuzumab biosimilar
Drug: Gemcitabine Hydrochloride
Drug: Irinotecan Hydrochloride

First Posted Date: 2020-01-02

Last Posted Date: 2020-01-02

Lead Sponsor: Jin-Hee Ahn

Target Recruit Count: 42

Registration Number: NCT04215159

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Phase 1

Recruiting

Conditions: Relapsed Neuroblastoma
Refractory Neuroblastoma

Interventions: Biological: Natural Killer Cells
Drug: Temozolomide
Drug: Irinotecan
Drug: Dinutuximab
Drug: Sargramostim

First Posted Date: 2019-12-26

Last Posted Date: 2024-02-16

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 31

Registration Number: NCT04211675

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Phase 2

Recruiting

Conditions: Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Stage IV Small Intestinal Adenocarcinoma AJCC v8
Metastatic Small Intestinal Adenocarcinoma
Stage III Small Intestinal Adenocarcinoma AJCC v8
Stage IIIB Small Intestinal Adenocarcinoma AJCC v8

Interventions: Drug: Paclitaxel
Drug: Fluorouracil
Biological: Ramucirumab
Drug: Irinotecan
Drug: Irinotecan Hydrochloride
Drug: Leucovorin
Drug: Leucovorin Calcium

First Posted Date: 2019-12-20

Last Posted Date: 2024-08-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 94

Registration Number: NCT04205968

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Swedish Medical Center-Ballard Campus, Seattle, Washington, United States

and more 459 locations